Aziyo Biologics, Inc. (Nasdaq: AZYO) and Sientra, Inc. (Nasdaq: SIEN) have joined forces to expand the distribution of Aziyo’s innovative SimpliDerm product line. This agreement will grant Sientra exclusive rights to market, sell and distribute SimpliDerm in the United States for select use in reconstruction surgery. This is a major step forward for the healthcare industry, as Aziyo’s SimpliDerm product line is designed to improve compatibility between medical devices and their patients.
Aziyo Biologics is excited to partner with Sientra and expand women’s access to biologic solutions necessary for successful reconstruction procedures. This agreement will help drive meaningful revenue growth and quickly and profitably expand the reach of our proprietary biologics platforms.
With this partnership, we are committed to our mission of improving compatibility between medical devices and the patients they serve. We look forward to leveraging Sientra’s highly-specialized commercial team, reach, and relationships to boost the SimpliDerm portfolio in reconstructive surgery.
SimpliDerm is a revolutionary pre-hydrated human acellular dermal matrix that uses a proprietary process to capture the beneficial growth factors of native dermis. This unique approach results in a pliable and conforming matrix with a remarkable sterility assurance level of 10-6, allowing for faster integration and more rapid revascularization while reducing the risk of inflammatory response. SimpliDerm is truly a remarkable advancement in skin regeneration technology.
At Sientra, we know that providing the best products to the most qualified surgeons is the key to achieving optimal results. That’s why we’ve partnered with Aziyo to offer our customers access to the innovative SimpliDerm portfolio, so they can provide the highest quality reconstruction solutions. By adding SimpliDerm to our portfolio, we’re not only reinforcing our commitment to being the leader in reconstruction, but also solidifying our path to profitability.
SimpliDerm is an amazing solution to help restore and replace damaged skin tissue. Whether you’re looking to repair a wound or just enhance your appearance, this innovative technology can be used to help you achieve your desired results. With its homologous uses of human integument, you can be sure that SimpliDerm will provide the highest quality of care.
About Aziyo Biologics
At Aziyo, we strive to make medical devices more compatible with the individuals who need them. We develop and commercialize biologic products to improve patient outcomes and enhance the lives of those who rely on implantable technologies. Our goal is to humanize medical devices and create a more positive experience for those who rely on them to live their lives.
Headquartered in Irvine, California, Sientra is a medical aesthetics company that is dedicated to revolutionizing the plastic surgery industry. With a mission to empower plastic surgeons and provide cutting-edge innovations, Sientra has developed a comprehensive portfolio of products designed to meet the needs of surgeons and their patients.
This includes their FDA-approved Sientra round and shaped breast implants, the groundbreaking Allox2® breast tissue expander, the Viality™ with AuraClens™ fat transfer system, and BIOCORNEUM®, the #1 performing, preferred, and recommended scar gel of plastic surgeons(*). By offering proprietary solutions and unparalleled partnerships, Sientra is redefining the plastic surgery experience.